Rossari Biotech Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹580Cr
- +22.6% YoY
- +13.1% QoQ
- Net profit
- ₹34Cr
- 0% YoY
- +6.3% QoQ
- Margin
- 12%
- −1 pp YoY
- −1 pp QoQ
Guidance rank: #45 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
Rossari Biotech targets mid-teens percentage growth in overall business revenue, with an annual growth rate around 15% (Page 4, 6). Consumer businesses expected to be profitable by FY27, with expansion fully online and higher Ethylene Oxide (EO) availability (Sunil Chari).
From Rossari Biotech Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Rossari Biotech targets mid-teens percentage growth in overall business revenue, with an annual growth rate around 15% (Page 4, 6).
- Ethoxylation capacity expansion expected to be commissioned by Q2 FY26, supporting growth in key segments (Page 4).
- HPPC (Home and Personal Care) business anticipated to grow in low double digits (~10%) in FY26, with some mid-teens growth possible due to new non-EO products (Page 6).
- Consumer and Institutional businesses grew 67% YoY to Rs. 299 crore in FY25 and expected to scale meaningfully in coming years, aiming for profitability by FY27 (Pages 4, 13).
2 more points from Rossari Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Rossari Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ongoing CAPEX focused on Ethoxylation capacity expansion expected to be operational by Q2 FY26.
- Additional CAPEX of Rs. 192 crore approved for phased expansions at subsidiaries Unitop Chemicals, Tristar Intermediates (Rs. 97 crore), and Rossari Biotech (Rs. 95 crore), to be commissioned by Q4 FY26.
- New expansions emphasize non-Ethylene Oxide (EO) products, backward integration including Esters and Monomers, and new chemistries in the Mellitic space.
- Investments include scaling up biosurfactant production with a large fermenter addition.
- R&D expansion underway, including a new center in Mumbai and increased staffing for innovation and future product development.
- Aim to enhance production capabilities, supply reliability, operational efficiency, and support scalable, sustainable growth.
2 more points from Rossari Biotech Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Rossari Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Rossari Biotech Ltd's call on order book
Create a free account to keep reading this call
Rossari Biotech Ltd — Quarterly revenue & net profit
Rossari Biotech Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 580 | 473 | +22.6% | 513 | +13.1% |
| Operating profit (EBITDA) | 69 | 64 | +7.8% | 65 | +6.2% |
| Operating margin | 12% | 13% | -1 pp | 13% | -1 pp |
| Profit before tax | 48 | 46 | +4.3% | 42 | +14.3% |
| Net profit (PAT) | 34 | 34 | 0% | 32 | +6.3% |
| EPS (₹) | 6.22 | 6.18 | +0.6% | 5.73 | +8.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹698 Cr, net profit ₹39 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Rossari Biotech's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Atul (Q4 FY25)
Consolidated revenue from operations for 2024-25: ₹5,583 cr, 18% increase YoY from ₹4,726 cr in 2023-24 (Page 36). Key concall takeaways from Atul Ltd's Q4…
- Vidhi Specialty (Q4 FY25)
109.5 Crs, up 40.2% YoY (from Rs. Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Chemcon Speciality Chemicals (Q4 FY25)
54.9 Crs, down 8% YoY from Rs. Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Valiant Organics (Q4 FY25)
Q4-FY25 revenue from operations (consolidated) was INR 2,038 million, a 15.3% year-on-year (YoY) increase from INR 1,768 million in Q4-FY24 (Page 12 and 10)…
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Rossari Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Rossari Biotech Ltd Q4 FY25 results?
Rossari Biotech targets mid-teens percentage growth in overall business revenue, with an annual growth rate around 15% (Page 4, 6). Consumer businesses expected to be profitable by FY27, with expansion fully online and higher Ethylene Oxide (EO) availability (Sunil Chari).
What is Rossari Biotech Ltd share price analysis?
Rossari Biotech Ltd currently shows a neutral. The stock trades at a P/E of 18.5 with a market cap of ₹2,786 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rossari Biotech Ltd planning capital expenditure?
Ongoing CAPEX focused on Ethoxylation capacity expansion expected to be operational by Q2 FY26.
Keep Rossari Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
